LLY

Business Context and Reporting Period

Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2006
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a smaller animal health segment included in reporting. The company focuses on neurosciences, endocrinology, oncology, and cardiovascular products.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Surge: Q2 2006 net income of $822.0 million represents a significant turnaround from a Q2 2005 net loss of $252.0 million. The prior year loss was driven by a $1.07 billion pre-tax charge for Zyprexa product liability settlements and reserves.
• Sales Growth: Net sales increased 5% in Q2 and 6% in the first half of 2006 compared to the prior year. Growth was driven by Cymbalta (+92% Q2), Forteo (+43% Q2), Alimta (+38% Q2), and Byetta.
• Margin Expansion: Gross margins improved by 1.5 percentage points in Q2 and 2.1 percentage points for the six-month period, attributed to favorable product mix and foreign exchange rates.
• Expense Increases: Operating expenses rose 5% year-over-year. Research and development increased 2% (Q2) and 3% (6 months), while marketing and administrative expenses increased 8% (Q2) and 6% (6 months) due to support for newer products.
• Cash Flow: Operating cash flow for the first six months of 2006 ($942.2 million) was lower than the prior year ($1,478.9 million), primarily due to changes in operating assets and liabilities.

Guidance, Outlook, and Risks

Management Guidance (2006)

• Q3 EPS: Expected to be $0.77 to $0.79 (5% to 8% growth vs. Q3 2005).
• Full Year EPS: Expected to be in the range of $3.10 to $3.20.
• Sales Growth: Expected to grow at the low end of the previous 7% to 9% guidance.
• Effective Tax Rate: Anticipated to be approximately 21%.
• Capital Expenditures: Expected to be flat at approximately $1.4 billion.

Material Risks and Contingencies

• Zyprexa Litigation: Significant ongoing product liability litigation alleging the drug causes diabetes. While a majority of claims have been settled, approximately 1,400 lawsuits and 850 tolled claims remain. An unfavorable outcome could materially impact results.
• Patent Challenges: Generic manufacturers (Teva, Reddy's, Barr) are challenging patents for Zyprexa, Evista, and Gemzar. Appeals are pending for Zyprexa; an unfavorable ruling could allow generic entry prior to 2011.
• Government Investigations: Civil investigations by the U.S. Attorney's office regarding marketing practices for Zyprexa, Prozac, and rebate agreements. Potential outcomes include fines, penalties, or criminal charges.
• European Facility Closures: The company is discussing the potential closure of three European facilities (two R&D, one manufacturing). If approved, this could result in significant severance and impairment charges.
• Patent Infringement Verdict: A jury awarded plaintiffs approximately $65 million in damages regarding Xigris and Evista patent infringement. Lilly plans to appeal.

Investor Verification Checklist

• Zyprexa Settlement Finality: Verify the status of the settlement agreements covering ~10,500 claimants and the conditions required for finalization.
• Patent Appeal Outcomes: Monitor the Federal Circuit Court of Appeals decision regarding the Zyprexa patent validity, which is critical for protecting revenue through 2011.
• European Restructuring: Confirm if the Board of Directors approves the closure of the three European sites and the magnitude of associated charges.
• Government Investigation Resolution: Track developments in the U.S. Attorney's civil investigation regarding marketing practices and Medicaid reporting.
• Insurance Recoveries: Assess the likelihood of collecting insurance proceeds for Zyprexa liabilities, as carriers are contesting coverage.